Duchenne Muscular Dystophy
Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy
August 4, 2025Research and Development Duchenne Muscular Dystophy, Hansa Biopharma, Rare Diseases, Sarepta Therapeutics, clinical trial, genetic disorder
Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the use of imlifidase as a …
Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy
January 12, 2024Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera
Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …
Sarepta’s Exondys 51 hit with negative CHMP opinion in Duchenne muscular dystrophy
September 24, 2018Research and Development, Sales and Marketing CHMP, Duchenne Muscular Dystophy, EMA, Europe, Exondys 51, pharma, sarepta
Sarepta Therapeutics has been rocked by a hurdle in its pursuit of regulatory approval in Europe, as the company revealed …
